+86-27-65522453 sales@sun-shinechem.com

Elafibranor(GFT505)

Catalog No.: 5112801
Cas No.: 923978-27-2
Purity : 98% by HPLC at 254nm 
5112801 - Elafibranor(GFT505) | CAS 923978-27-2

Catalog number : 5112801

CAS number : 923978-27-2

分子式 : C22H24O4S 

分子量 : 384.49 

Iupac 化学名称 : (E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid 

Smile : CC(C)(OC1=C(C)C=C(/C=C/C(C2=CC=C(SC)C=C2)=O)C=C1C)C(O)=O

InChiKey : AFLFKFHDSCQHOL-IZZDOVSWSA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDS电话:+86-27-65522453 | Email:sales@sun-shinechem.com
同义词GFT505,SureCN815512,GFT-505,GFT 505 
英文同义词GFT505,SureCN815512,GFT-505,GFT 505 
分子式C22H24O4S 
分子量384.49 
外观light-yellow solid 
纯度98% by HPLC at 254nm 
可溶性Soluble in DMSO 
存储3 years -20ºCpowder;6 months-80ºCin solvent 
运输条件Shipped under ambient temperature. 
SmileCC(C)(OC1=C(C)C=C(/C=C/C(C2=CC=C(SC)C=C2)=O)C=C1C)C(O)=O
InChiKeyAFLFKFHDSCQHOL-IZZDOVSWSA-N
InChiInChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
Coming soon.

Elafibranor (GFT505) is Genfits lead pipeline product. Its an oral once-daily treatment, positioned as a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). Based on the beneficial activities that it demonstrates on the different features of the pathology, Elafibranor represents the ideal drug for NASH patients, including those suffering from the most severe forms of the disease.

The new non-proprietary name, Elafibranor, reflects the first-in-class nature of the drug candidate, since it does not contain a pre-existing INN stem. The novel pre-stem -fibranor may thus become an established stem over time, as other later developed drugs are recognized to be related in structure or activity.

Phase 3 launch in 2015

In March 2015, Genfit announced topline results from the phase 2b GOLDEN-505 trial in NASH (GFT505-2127) in which Elafibranor has been tested for clinical efficacy in NASH in a 1-year liver biopsy-based Phase 2b trial (GFT505-2127), one of the largest interventional studies ever conducted in NASH:

 

923978-27-2 - Request Bulk Quote

×
923978-27-2 - Request Bulk Quote
Change